Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New radioactive drug takes aim at hard-to-treat prostate cancer

NCT ID NCT06229366

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This early-phase trial tests an experimental drug called [Ac-225]-PSMA-62 in 142 men with a specific type of prostate cancer that shows up on a PSMA scan. The drug delivers a tiny dose of radiation directly to cancer cells. The main goals are to find the safest dose and to check for side effects and early signs that the drug is working.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • BC Cancer Vancouver

    Vancouver, V5Z4E6, Canada

  • Centre Hospitalier Universite de QUEBEC

    Québec, G1J 1Z4, Canada

  • Hopital De Chicoutimi

    Saguenay, G7H 5H6, Canada

  • Jewish General Hospital

    Montreal, H3T 1E2, Canada

  • Juravinski

    Hamilton, L8V 5C2, Canada

  • McGill University

    Montreal, H4A 3J1, Canada

  • Princess Margaret Cancer Centre

    Toronto, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.